4.3 Article

Host response to Staphylococcus aureus cytotoxins in children with cystic fibrosis

Journal

JOURNAL OF CYSTIC FIBROSIS
Volume 15, Issue 5, Pages 597-604

Publisher

ELSEVIER SCIENCE BV
DOI: 10.1016/j.jcf.2015.12.023

Keywords

Staphylococcus aureus; Cystic fibrosis; Exotoxins; LukAB; Serology

Funding

  1. National Institutes of Health
  2. Cystic Fibrosis Foundation: CTSA award from the National Center for Advancing Translational Sciences [UL1TR000445]
  3. CFF Center Grant [C108-12, 177]
  4. CFF Third Year Clinical Cystic Fibrosis Fellowship Grant [CHADHA13D0]
  5. [R01AI105129]

Ask authors/readers for more resources

Background: Staphylococcus aureus is one of the earliest bacterial pathogens to colonize the lungs of children with cystic fibrosis and is an important contributor to pulmonary exacerbations. The adaptive host response to S. aureus in cystic fibrosis remains inadequately defined and has important implications for pathogenesis and potential interventions. The objectives of this study were to determine the functional antibody response to select staphylococcal exotoxins (LukAB, alpha-hemolysin, and PVL) in children with cystic fibrosis and to evaluate the relationship of this response with pulmonary exacerbations. Methods: Fifty children with cystic fibrosis were enrolled and followed prospectively for 12 months. Clinical characteristics and serologic profiles were assessed at routine visits and during pulmonary exacerbations, and functional antibody assessments were performed to measure neutralization of LukAB-mediated cytotoxicity. Results: For each antigen, geometric mean titers were significantly higher if S. aureus was detected at the time of exacerbation. For LukAB, geometric mean titers were significantly higher at exacerbation follow-up compared to titers during the exacerbation, consistent with expression during human disease, and the humoral response capably neutralized LukAB-mediated cytotoxicity. Moreover, the presence of a positive S. aureus culture during a pulmonary exacerbation was associated with 31-fold higher odds of having a LukA. titer >= 1:160, suggesting potential diagnostic capability of this assay. Conclusions: The leukotoxin LukAB is expressed by S. aureus and recognized by the human adaptive immune response in the setting of pulmonary infection in cystic fibrosis. Anti-LukAB antibodies were not only predictive of positive staphylococcal culture during exacerbation, but also functional in the neutralization of this toxin. (C) 2016 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.3
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available